Our Therapeutic Portfolio
This section contains information and fact sheets about Boehringer Ingelheim’s therapeutic portfolio.
Research & Development is Key at Boehringer Ingelheim
During the past decade from 2002 to 2011, Boehringer Ingelheim conducted or sponsored 1,348 studies with 111 substances in 91 countries from all regions of the world. The studies enrolled approximately 1 million patients during this decade, of which about 400,000 were in phase I–IV studies and nearly 600,000 in PMS studies (post-marketing surveillance).
A Guide to our Therapeutic Areas
There are five major therapeutic areas in which Boehringer Ingelheim either has products on the market or is actively working on getting new treatments approved. Please find further information and fact sheets on the different indications in the tabs below.
Boehringer Ingelheim carries out research and development to find new therapeutic approaches for the treatment of cardiometabolic diseases in following areas:
- Atherosclerosis
- Diabetes
- Metabolic syndrome
- Obesity
- Thrombo-embolic diseases
-
Atrial Fibrillation and Stroke
Atrial fibrillation (AF) is a problem that causes the heart to beat with an irregular rhythm. Read more about atrial fibrillation and stroke and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Hypertension
Hypertension or high blood pressure is traditionally defined as a persistent systolic blood pressure of greater than 140mmHg and/or diastolic blood pressure of greater than 90mmHg. Read more about hypertension and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Type 2 Diabetes
Type 2 diabetes (T2D) is a chronic progressive condition characterised by increased insulin resistance and impaired ß-cell function resulting in inadequate insulin secretion. Read more about type 2 diabetes and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Venous Thromboembolism
Venous thromboembolism (VTE) refers to blood clots (thrombi) which originate in the veins, comprising deep vein thrombosis (DVT) and its potentially fatal acute complication, pulmonary embolism (PE). Read more about venous thromboembolism and Boehringer Ingelheim’s research in it in the fact sheet below.
The introduction of new treatments for infectious diseases has accelerated in recent decades and this trend is projected to continue in the coming years. In spite of the advances of the last two decades, exemplified by the enormously improved management of HIV-infected patients as the result of combination antiretroviral therapy, many infectious diseases remain poorly treated. Our focus of infectious diseases research is on pathogens responsible for very significant human diseases where effective therapy is lacking.
-
Hepatitis C
Hepatitis C is an infectious disease of the liver caused by a virus. Read more about hepatitis C and Boehringer Ingelheim’s research in it in the fact sheet below.
-
HIV
The human immunodeficiency virus (HIV) is a retrovirus that can lead to acquired immune deficiency syndrome (AIDS). HIV attacks those cells of the immune system that protect the body. The virus uses these cells to reproduce. Read more about HIV and Boehringer Ingelheim’s research in it in the fact sheet below.
Progressive degeneration of the nerve cells is typical for all chronic neurological diseases. Our scientists are investigating ways of identifying and developing new treatments which can intervene in the process.
-
Parkinson’s Disease
Parkinson’s disease (PD) is an age-related, progressive neurodegenerative disease of the brain that affects nerve cells involved with movement. Read more about parkinson’s disease and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Restless Legs Syndrome
Restless legs syndrome (RLS) is a common neurological disorder characterised by an uncontrollable urge to move the legs, usually accompanied or caused by unpleasant sensations in the legs. Read more about restless legs syndrome and Boehringer Ingelheim’s research in it in the fact sheet below.
Drug discovery at Boehringer Ingelheim aims to develop new cancer medicines with clear therapeutic benefit. We pursue the search for new cancer drugs along several fronts, including cell surface receptor signalling pathways, cell cycle regulation, cancer cell survival and drug resistance as well as tumour angiogenesis.
-
Breast Cancer
Breast cancer is the term used to describe the uncontrolled growth of abnormal cells in the breast tissue, most commonly in the lobules (milk producing glands) and ducts (the passages that carry milk to the nipples), leading to the formation of a solid lump or tumour. Read more about breast cancer and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Head and Neck Cancer
Head and neck cancer is the term used to describe a wide range of malignant tumours originating in the upper aerodigestive tract (UADT), including the oral cavity, larynx, pharynx and nasopharynx. Read more about head and neck cancer and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Lung Cancer
Lung cancer is the term used to describe growth of abnormal cells lining the air passages inside the lung tissue. Read more about lung cancer and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Ovarian Cancer
Ovarian cancer is an abnormal growth of tissue that develops into a heterogeneous group of malignancies in a woman's ovaries (female reproductive glands in which the ovar, or eggs, are formed). Read more about ovarian cancer and Boehringer Ingelheim’s research in it in the fact sheet below.
Boehringer Ingelheim is one of the leading pharmaceutical companies worldwide in the treatment of airway diseases. Research and development are focused particularly on asthma, chronic obstructive pulmonary diseases (COPD), and idiopathic pulmonary fibrosis.
-
Asthma
Asthma is a chronic disease characterised by airway inflammation and bronchoconstriction. Read more about asthma and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Chronic Obstructive Pulmonary Disease (COPD)
COPD is characterised by shortness of breath (or dyspnoea), coughing, wheezing and increased sputum (mucus or phlegm) production. Read more about COPD and Boehringer Ingelheim’s research in it in the fact sheet below.
-
Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a progressive and severely debilitating lung disease associated with high mortality. Read more about IPF and Boehringer Ingelheim’s research in it in the fact sheet below.
